Medical director

Better risk stratification and lower hospital costs

The suPARnostic® test provides improved risk stratification of all patients in the Emergency Department.
This allows the staff to discharge more non-acute patients earlier, to reduce stress, crowding and hospital costs. It also generates more time for the staff to focus on high-risk patients, enabling them to provide even better clinical care.

Eliminate doubt in clinical decisions

suPARnostic® is the only CE-IVD certified product range applied for clinical determination of suPAR in human plasma and serum. It enables Healthcare Professionals to make fast clinical decisions based on prognostic evidence across diseases.

A low suPAR level indicates a good prognosis and supports the decision to discharge the patient.
A high suPAR level indicates presence, progression and severity of disease, organ damage and risk of mortality, and supports further clinical attention.

Get More Info

Documented by 600+ publications

Here you can find a short summary of the research done on suPAR within 12 groups of disease areas and see how the suPAR level is affected within each type of disease.

suPAR Publications
Disease Areas

“The key challenge for the ER is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”

MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen

Free guide

Are you working with triage?
Get our guide to better triage in 5 steps to increase your triage workflow in the Emergency Department.

Get significant cost savings

suPARnostic® can identify patients who can be sent home without hospitalization and help avoid unnecessary treatments and readmissions.
A study shows that for every 4 patients received, the hospital can save one hospital bed for 24 hours.*

*Schultz et al. Disease Markers, 2019, 10;1-8A sub study of the interventional TRIAGE III trial, comparing patients with a valid suPAR measurement at admission to those without in EDs at two university hospitals in the Capital Region of Denmark.

Our products

suPARnostic® is developed to measure the amount of suPAR protein (soluble urokinase Plasminogen Activator Receptor) in human blood.
It is the only CE-IVD certified product range applied for clinical determination of suPAR in human plasma and serum.
The suPARnostic® brand consists of the following 3 products:

TurbiLatex

For Automated Systems

See Product

Quick Triage Test

A Point of Care Solution

See Product

ELISA Assay

For Clinical and Research Use

See Product